Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
[Congress] [EN] Pharmabiotics Online, 28-29 April 2021
Home . Resources . [Congress] [EN] Pharmabiotics Online, 28-29 April 2021
Organised by the Pharmabiotic Research Institute, Pharmabiotics is an event dedicated to medicinal microbiotic products. This event brings together online all actors involved in the international human microbiome community.
Oncodesign BU Service will be present at Pharmabiotics !
Oncodesign BU Service is an innovation-based solutions and expertise provider in Drug Discovery in Oncology, Immuno-oncology and Inflammatory Diseases.
Discover SOLO- Microbiome: this offer enables to assist you in microbiome therapeutic project and strategy
This offering encloses multiple innovative hit-finding/screening capabilities, medicinal chemistry, computational chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology, pharmaco-imaging/theranostic and safety assessment all applied in one-stop shop to drug discovery programs in oncology, immuno-oncology, auto-immune/ inflammatory diseases.
Oncodesign can be your partner:
to study the relationship between imbalances in microbiota and the disease of interest,
to define the role of microbiota in precision diagnosis and personalized treatment,
to develop/evaluate therapeutics derived from microbiota.
Discover Oncodesign models for pathologies related to microbiota disorders and all assays/readouts that allow us to evaluate in vitro and in vivo the impact of bacteria or derived products on cancer and inflammatory diseases and the immune responses in such context.